Cell lines include EBV-positive Raji cells (ATCC CCL-86) [59 (link)], EBV-negative Elijah B cells (kindly provided by Prof. A.B. Rickinson), 293 cells (ATCC CRL-1573) [60 (link)], T cells specific for EBNA1 3E10, EBNA3C 5H11, gp350 1D6 and BNRF1 VSD epitopes (kindly provided by Prof. J. Mautner) and autologous LCLs (kindly provided by Prof. J. Mautner). Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque Plus and primary B cells were isolated using Dynabeads CD19 Pan B (Invitrogen) and DETACHaBEAD CD19 kit (Invitrogen). RPMI containing 10% fetal calf serum (F7524, Sigma) was used to culture 293, Raji and Elijah cells. T-cell clones and lines were cultured as previously described [17 (link),35 (link)].
Detachabead cd19 kit
Manufactured by Thermo Fisher Scientific
The DETACHaBEAD CD19 kit is a laboratory product designed for the isolation and enrichment of CD19-positive cells from a variety of biological samples. The kit utilizes magnetic beads coated with anti-CD19 antibodies to capture and separate the target cells.
Automatically generated - may contain errors
2 protocols using detachabead cd19 kit
1
Isolation and Culture of EBV-associated Cells
2
Prognostic Value of circCTNNA1 in MCL
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
This study enrolled a total of 56 MCL patients (34 cases of blastoid variant and 22 cases of pleomorphic variant; 63.4+/−6,6 years; 32 males and 24 females) and 56 healthy controls (63.5+/−6,5 years; 32 males and 24 females) at Zibo Central Hospital from May 2014 to May 2016. Ethics approval was obtained from the Ethics Committee of this hospital. Two groups of participants showed similar distributions of age and gender. The diagnosis of MCL was performed according to WHO classification of hematological neoplasms. Patients with leukemic phase MCL were excluded from this study. Fasting blood samples were collected from both groups of participants prior to the initiation of therapies. DETACHaBEAD CD19 Kit (Invitrogen) was used to separate B lymphocytes from all blood samples. Purity of higher than 90% was reached in all samples of B lymphocytes. All patients signed the informed consent. MCL patients were treated with chemoimmunotherapy R-CHOP, in which rituximab, cyclophosphamide, hydroxydaunomycin, vincristine sulfate and prednisone were included.
All 56 MCL patients were followed up for 5 years to evaluate the prognostic value of circCTNNA1 for MCL. Patients were visited through outpatient visit and telephone in some cases. All patients either died of MCL or survived until the end of follow-up. This study was conducted in accordance with the Declaration of Helsinki.
All 56 MCL patients were followed up for 5 years to evaluate the prognostic value of circCTNNA1 for MCL. Patients were visited through outpatient visit and telephone in some cases. All patients either died of MCL or survived until the end of follow-up. This study was conducted in accordance with the Declaration of Helsinki.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!